The Role of C-reactive Protein in Patient Risk Stratification and Treatment

Atherosclerosis is a chronic inflammatory disease. Several circulating inflammatory markers have been proposed for clinical use due to their ability to predict future cardiovascular events and may be useful for identifying people at high risk who might benefit from specific treatment to reduce this...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ramón Arroyo-Espliguero, María C Viana-Llamas, Alberto Silva-Obregón, Pablo Avanzas
Formato:	article
Lenguaje:	EN
Publicado:	Radcliffe Medical Media 2021
Materias:	Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/acd02d4c12464c03a725034e018e8fd6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:acd02d4c12464c03a725034e018e8fd6
record_format	dspace
spelling	oai:doaj.org-article:acd02d4c12464c03a725034e018e8fd62021-12-04T16:04:40ZThe Role of C-reactive Protein in Patient Risk Stratification and Treatment10.15420/ecr.2020.491758-37641758-3756https://doaj.org/article/acd02d4c12464c03a725034e018e8fd62021-07-01T00:00:00Zhttps://www.ecrjournal.com/articleindex/ecr.2020.49https://doaj.org/toc/1758-3756https://doaj.org/toc/1758-3764Atherosclerosis is a chronic inflammatory disease. Several circulating inflammatory markers have been proposed for clinical use due to their ability to predict future cardiovascular events and may be useful for identifying people at high risk who might benefit from specific treatment to reduce this risk. Moreover, the identification of new therapeutic targets will allow the development of drugs that can help reduce the high residual risk of recurrence of cardiovascular events in patients with coronary artery disease. The clinical benefits of reducing recurrent major cardiovascular events recently shown by canakinumab and colchicine have renewed the cardiology community’s interest in inflammation as an aetiopathogenic mechanism for atherosclerosis. This review explores the use of C-reactive protein, which is the most frequently studied biomarker in this context; the concept of residual risk in primary and secondary cardiovascular prevention; and the current recommendations in international guidelines regarding the role of this inflammatory biomarker in cardiovascular risk stratification.Ramón Arroyo-EspligueroMaría C Viana-LlamasAlberto Silva-ObregónPablo AvanzasRadcliffe Medical MediaarticleDiseases of the circulatory (Cardiovascular) systemRC666-701ENEuropean Cardiology Review , Vol 16, Iss , Pp - (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	Diseases of the circulatory (Cardiovascular) system RC666-701 Ramón Arroyo-Espliguero María C Viana-Llamas Alberto Silva-Obregón Pablo Avanzas The Role of C-reactive Protein in Patient Risk Stratification and Treatment
description	Atherosclerosis is a chronic inflammatory disease. Several circulating inflammatory markers have been proposed for clinical use due to their ability to predict future cardiovascular events and may be useful for identifying people at high risk who might benefit from specific treatment to reduce this risk. Moreover, the identification of new therapeutic targets will allow the development of drugs that can help reduce the high residual risk of recurrence of cardiovascular events in patients with coronary artery disease. The clinical benefits of reducing recurrent major cardiovascular events recently shown by canakinumab and colchicine have renewed the cardiology community’s interest in inflammation as an aetiopathogenic mechanism for atherosclerosis. This review explores the use of C-reactive protein, which is the most frequently studied biomarker in this context; the concept of residual risk in primary and secondary cardiovascular prevention; and the current recommendations in international guidelines regarding the role of this inflammatory biomarker in cardiovascular risk stratification.
format	article
author	Ramón Arroyo-Espliguero María C Viana-Llamas Alberto Silva-Obregón Pablo Avanzas
author_facet	Ramón Arroyo-Espliguero María C Viana-Llamas Alberto Silva-Obregón Pablo Avanzas
author_sort	Ramón Arroyo-Espliguero
title	The Role of C-reactive Protein in Patient Risk Stratification and Treatment
title_short	The Role of C-reactive Protein in Patient Risk Stratification and Treatment
title_full	The Role of C-reactive Protein in Patient Risk Stratification and Treatment
title_fullStr	The Role of C-reactive Protein in Patient Risk Stratification and Treatment
title_full_unstemmed	The Role of C-reactive Protein in Patient Risk Stratification and Treatment
title_sort	role of c-reactive protein in patient risk stratification and treatment
publisher	Radcliffe Medical Media
publishDate	2021
url	https://doaj.org/article/acd02d4c12464c03a725034e018e8fd6
work_keys_str_mv	AT ramonarroyoespliguero theroleofcreactiveproteininpatientriskstratificationandtreatment AT mariacvianallamas theroleofcreactiveproteininpatientriskstratificationandtreatment AT albertosilvaobregon theroleofcreactiveproteininpatientriskstratificationandtreatment AT pabloavanzas theroleofcreactiveproteininpatientriskstratificationandtreatment AT ramonarroyoespliguero roleofcreactiveproteininpatientriskstratificationandtreatment AT mariacvianallamas roleofcreactiveproteininpatientriskstratificationandtreatment AT albertosilvaobregon roleofcreactiveproteininpatientriskstratificationandtreatment AT pabloavanzas roleofcreactiveproteininpatientriskstratificationandtreatment
_version_	1718372694352723968

The Role of C-reactive Protein in Patient Risk Stratification and Treatment

Ejemplares similares